Adults aged 18–64 years with severe immunocompromise are recommended to receive COVID-19 vaccine every year and can consider a second annual dose
Adults aged 18–64 years with severe immunocompromise are recommended to receive COVID-19 vaccine every year and can consider a second annual dose, approximately 6 months apart, based on a risk benefit assessment.
An annual COVID-19 vaccine dose is funded through the NIP for adults aged 18–64 years with severe immunocompromise. For details see the National Immunisation Program Schedule.
People who have had haematopoietic stem cell transplant or CAR-T cell therapy may have reduced immune response to vaccination and require 2 priming doses, given 8 weeks apart, when revaccinated for the first time.
Risk-benefit considerations for a second annual dose may include:
- Age-related risk of COVID-19 and its complications: COVID-19 can occur at any age, but the risk of severe disease in adults increases with age.
- Potential risks associated with COVID-19 vaccination: Most adverse events following COVID-19 vaccination are mild to moderate and self-limited. Very rare but serious adverse events such as myocarditis and pericarditis have been reported with the highest incidence amongst adolescent and young adult males after a second mRNA vaccine dose.6-8
- Individual’s personal preferences: Personal attitudes towards preventing severe COVID-19 and related complications may influence decisions about vaccination
See Table. Types of medical conditions and immunosuppressive therapy and associated levels of immunocompromise.
For additional information about conditions associated with increased risk of severe outcomes from COVID-19, see Table. Example conditions associated with increased risk of severe outcomes from COVID-19.